Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abobotulinum Toxin A for Raynaud's Phenomenon Symptoms
NCT03639766Phase 4Terminated
- Sponsor
- University of Central Florida
- Start
- Aug 2018
- Primary completion
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of botulinum toxin type A in Raynaud phenomenon (2 arms), sponsored by University of Central Florida. Primary endpoint: Raynaud's Condition Score at 12 months. Started Aug 2018; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT03639766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639766.